Back

Integrated kidney and urine proteomics define encrypted antimicrobial peptides as effectors of host defence in human pyelonephritis

Borgards, L.; Voss, H. L.; Tautges, S.; Siebels, B.; Pylaeva, E.; Spangenberg, P.; Siemes, D.; Krisp, C.; Schmitz, J.; Cinkul, L.; Damilola, A.; Hilger, A.; Szymczak, P.; Aust, A.; Braesen, J. H.; Szczurek, E.; de la Fuente-Nunez, C.; Jablonska, J.; Soehnlein, O.; Dobrindt, U.; Schlueter, H.; von Vietinghoff, S.; Wagenlehner, F.; Engel, D. R.; Shevchuk, O.

2026-04-14 immunology
10.64898/2026.04.10.717476 bioRxiv
Show abstract

Antimicrobial peptides (AMPs) are key effectors of host defence, however, their functional deployment across renal tissue and urine in pyelonephritis (PN) remains incompletely understood. Here, we integrate kidney and urine proteomics with urinary peptidomics and computational prediction to define AMP organisation and function. Proteomic analysis indicated coordinated induction of multiple AMPs in infected kidneys. These patterns were recapitulated in the urinary proteome, where AMP abundance correlated with leukocyte counts. Multiplex immunofluorescence microscopy localised these AMPs to myeloid cells, identifying them as central effector sources. Importantly, analysis of the urine peptidome revealed multiple encrypted AMPs (EPs), which arise from proteolytic processing of precursor proteins. To systematically assess their relevance for host defence, we applied an ensemble of machine learning-based predictors to prioritise candidates with activity in the urinary environment. This approach identified several potential EPs, among which the S100A12-derived peptide Calcitermin was confirmed in patient urine. Furthermore, it exerts antibacterial activity against uropathogenic E. coli (UPEC) and modulates myeloid cell responses. Together, these findings define a coordinated and compartmentalised AMP defence programme in human PN that extends beyond increased peptide expression, highlighting EPs as functionally relevant effectors with therapeutic potential.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 10%
14.6%
2
Cell Reports Medicine
140 papers in training set
Top 0.3%
6.8%
3
Science Translational Medicine
111 papers in training set
Top 0.3%
6.3%
4
Immunity
58 papers in training set
Top 0.9%
6.3%
5
Science Immunology
81 papers in training set
Top 0.4%
4.3%
6
Nature Immunology
71 papers in training set
Top 0.4%
4.3%
7
Cell
370 papers in training set
Top 5%
3.9%
8
Cell Reports
1338 papers in training set
Top 14%
3.6%
50% of probability mass above
9
JCI Insight
241 papers in training set
Top 1%
3.6%
10
EMBO Molecular Medicine
85 papers in training set
Top 0.6%
3.6%
11
Frontiers in Immunology
586 papers in training set
Top 2%
3.2%
12
Advanced Science
249 papers in training set
Top 7%
2.7%
13
Journal of Clinical Investigation
164 papers in training set
Top 2%
1.9%
14
Molecular & Cellular Proteomics
158 papers in training set
Top 1%
1.7%
15
eLife
5422 papers in training set
Top 42%
1.7%
16
Science Advances
1098 papers in training set
Top 20%
1.5%
17
PLOS Biology
408 papers in training set
Top 12%
1.3%
18
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 38%
1.2%
19
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.1%
20
Molecular Systems Biology
142 papers in training set
Top 1%
0.9%
21
Genome Medicine
154 papers in training set
Top 7%
0.9%
22
Cell Host & Microbe
113 papers in training set
Top 4%
0.9%
23
Kidney International Reports
14 papers in training set
Top 0.2%
0.8%
24
Gut
36 papers in training set
Top 0.9%
0.7%
25
Brain
154 papers in training set
Top 5%
0.7%
26
Gastroenterology
40 papers in training set
Top 2%
0.7%
27
iScience
1063 papers in training set
Top 32%
0.7%
28
Cell Systems
167 papers in training set
Top 13%
0.7%
29
Journal of Extracellular Vesicles
50 papers in training set
Top 0.5%
0.6%
30
PLOS Pathogens
721 papers in training set
Top 10%
0.6%